The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease

Clinical Nutrition

Volumn 30, Issue 1, 2011, Pages 6-19

  Shapiro, Haim ^a   Tehilla, Miryam ^a   Attal Singer, Joelle ^a,b   Bruck, Rafael ^b,c   Luzzatti, Rachel ^d   Singer, Pierre ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d Clalit Health Medical Organization   (Israel)

Author keywords

Fish oil; Long chain omega 3 fatty acids; Nonalcoholic fatty liver disease

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LIPID; OMEGA 3 FATTY ACID; OMEGA 3 FATTY ACID ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL FATTY ACID DEFICIENCY; FAT INTAKE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MEDICAL LITERATURE; MEDLINE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; REVIEW;

CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FATTY LIVER; FISH OILS; HUMANS; LIVER; NUTRITIONAL PHYSIOLOGICAL PHENOMENA;

EID: 79451476075     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2010.06.001     Document Type: Review

References (82)

1. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725. American Gastroenterological Association.
2. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317.
3. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757. American Heart Association. Nutrition Committee.
4. Botham K.M., Mayes P.A. Lipids of physiologic significance. Harper's illustrated biochemistry 2006, 121-131. McGraw Hill. 27th ed. D.K. Granner, V.W. Rodwell (Eds.).
5. Shi Y., Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 2004, 3:695-710.
6. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009, 48(1):1-26.
7. Alfin-Slater R.B., Bernick S. Changes in tissue lipids and tissue histology resulting from essential fatty acid deficiency in rats. Am J Clin Nutr 1958, 6:613-624.
8. Burr G.O., Burr M.M. On the nature and role of the fatty acids essential in nutrition. J Biol Chem 1930, 86:587-621.
9. Higdon J. Essential fatty acids. An evidence-based approach to dietary phytochemicals 2006, 78-99. Thieme medical publishers, New York. J. Higdon (Ed.).
10. Werner A., Havinga R., Kuipers F., Verkade H.J. Treatment of EFA deficiency with dietary triglycerides or phospholipids in a murine model of extrahepatic cholestasis. Am J Physiol Gastrointest Liver Physiol 2004, 286:G822-G832.
11. Alwayn I.P., Andersson C., Zauscher B., Gura k., Nosé V., Puder M. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 2005, 79:606-608.
12. Calder P.C. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2007, 77:327-335.
13. Sacerdoti D., Gatta A., McGiff J.C. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 2003, 72:51-71.
14. Goyens P.L., Spilker M.E., Zock P.L., Katan M.B., Mensink R.P. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr 2006, 84:44-53.
15. Burdge G. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr Opin Clin Nutr Metab Care 2004, 7:137-144.
16. Schaeffer L., Gohlke H., Müller M., Heid I.M., Palmer L.J., Kompauer I., et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006, 15:1745-1756.
17. Zhou Y.E., Kubow S., Dewailly E., Julien P., Egeland G.M. Decreased activity of desaturase 5 in association with obesity and insulin resistance aggravates declining long-chain n-3 fatty acid status in Cree undergoing dietary transition. Br J Nutr 2009, 2:1-7.
18. Bantle J.P., Wylie-Rosett J., Albright A.L., Apovian C.M., Clark N.G., Franz M.J., et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008, 31(Suppl. 1):S61-S78. American Diabetes Association.
19. De Caterina R., Madonna R., Bertolotto A., Schmidt E.B. n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 2007, 30:1012-1026.
20. Ervin R.B., Wright J.D., Wang C.Y., Kennedy-Stephenson J. Dietary intake of fats and fatty acids for the United States population: 1999-2000. Adv Data 2004, 348:1-6.
21. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19-30.
22. Bays H.E., Tighe A.P., Sadovsky R., Davidson M.H. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008, 6:391-409.
23. Chan D.C., Watts G.F., Mori T.A., Barrett P.H., Redgrave T.G., Beilin L.J. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 2003, 77:300-307.
24. Chan D.C., Watts G.F., Barrett P.H., Beilin L.J., Redgrave T.G., Mori T.A. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002, 51(8):2377-2386.
25. Faeh D., Minehira K., Schwarz J.M., Periasamy R., Park S., Tappy L. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 2005, 54:1907-1913.
26. Mostad I.L., Bjerve K.S., Bjorgaas M.R., Lydersen S., Grill V. Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr 2006, 84:540-550.
27. Pan M., Cederbaum A.I., Zhang Y.L., Ginsberg H.N., Williams K.J., Fisher E.A. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004, 113:1277-1287.
28. Krauss R.M. Hold the antioxidants and improve plasma lipids?. J Clin Invest 2004, 113:1253-1255.
29. Utzschneider K.M., Kahn S.E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006, 91:4753-4761.
30. Fabbrini E., Mohammed B.S., Magkos F., Korenblat K.M., Patterson B.W., Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008, 134:424-431.
31. Jucker B.M., Cline G.W., Barucci N., Shulman G.I. Differential effects of safflower oil versus fish oil feeding on insulin-stimulated glycogen synthesis, glycolysis, and pyruvate dehydrogenase flux in skeletal muscle: a 13C nuclear magnetic resonance study. Diabetes 1999, 48:134-140.
32. Xiao C., Giacca A., Carpentier A., Lewis G.F. Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans. Diabetologia 2006, 49:1371-1379.
33. Sirtori C.R., Crepaldi G., Manzato E., Mancini M., Rivellese A., Paoletti R., et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis 1998, 137:419-427.
34. Svegliati-Baroni G., Candelaresi C., Saccomanno S., Ferretti G., Bachetti T., Marzioni M., et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006, 169:846-860.
35. Buettner R., Parhofer K.G., Woenckhaus M., Wrede C.E., Kunz-Schughart L.A., Schölmerich J., et al. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 2006, 36:485-501.
36. Levy J.R., Clore J.N., Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004, 39:608-616.
37. Shirouchi B., Nagao K., Inoue N., Ohkubo T., Hibino H., Yanagita T. Effect of dietary omega 3 phosphatidylcholine on obesity-related disorders in obese Otsuka Long-Evans Tokushima fatty rats. J Agric Food Chem 2007, 55(17):7170-7176.
38. Yamazaki T., Nakamori A., Sasaki E., Wada S., Ezaki O. Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddy mice. Hepatology 2007, 46. 1779-1190.
39. Sekiya M., Yahagi N., Matsuzaka T., Najima Y., Nakakuki M., Nagai R., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003, 38:1529-1539.
40. El-Badry A.M., Moritz W., Contaldo C., Tian Y., Graf R., Clavien P.A. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 2007, 45:855-863.
41. González-Périz A., Horrillo R., Ferré N., Gronert K., Dong B., Morán-Salvador E., et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by {omega}-3 fatty acids: a role for resolvins and protectins. FASEB J 2009, 23(6):1946-1957.
42. Martin P.G., Guillou H., Lasserre F., Déjean S., Lan A., Pascussi J.M., et al. Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatology 2007, 45(3):767-777.
43. Ishii H., Horie Y., Ohshima S., Anezaki Y., Kinoshita N., Dohmen T., et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol 2009, 50:562-571.
44. Larter C.Z., Yeh M.M., Cheng J., Williams J., Brown S., dela Pena A., et al. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol 2008, 23:267-275.
45. Alwayn I.P., Gura K., Nosé V., Zausche B., Javid P., Garza J., et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005, 57:445-452.
46. Kajikawa S., Harada T., Kawashima A., Imada K., Mizuguchi K. Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. Prostaglandins Leukot Essent Fatty Acids 2009, 80(4):229-238.
47. Reddy J.K., Rao M.S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006, 290:G852-G858.
48. Clarke S.D. The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol 2004, 15(1):13-18.
49. Jump D.B. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 2008, 19:242-247.
50. Sethi S., Ziouzenkova O., Ni H., Wagner D.D., Plutzky J., Mayadas T.N. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002, 100:1340-1346.
51. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006, 58:726-741.
52. Awazawa M., Ueki K., Inabe K., Yamauchi T., Kaneko K., Okazaki Y., et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem Biophys Res Commun 2009, 382:51-56.
53. Kratz M., Swarbrick M.M., Callahan H.S., Matthys C.C., Havel P.J., Weigle D.S. Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. Am J Clin Nutr 2008, 87:347-353.
54. Itoh M., Suganami T., Satoh N., Tanimoto-Koyama K., Yuan X., Tanaka M. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007, 27:1918-1925.
55. Krebs J.D., Browning L.M., McLean N.K., Rothwell J.L., Mishra G.D., Moore C.S., et al. Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes (Lond) 2006, 30:1535-1544.
56. Nomura S., Inami N., Shouzu A., Omoto S., Kimura Y., Takahashi N., et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 2009, 20(1):16-22.
57. Artmann A., Petersen G., Hellgren L.I., Boberg J., Skonberg C., Nellemann C., et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008, 1781:200-212.
58. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67:1954-1967.
59. Zeisel S.H. Choline: critical role during fetal development and dietary requirements in adults. Annu Rev Nutr 2006, 26:229-250.
60. Li Z., Agellon L.B., Allen T.M., Umeda M., Jewell L., Mason A., et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006, 3:321-331.
61. Li Z., Vance D.E. Phosphatidylcholine and choline homeostasis. J Lipid Res 2008, 49:1187-1194.
62. Singer P., Shapiro H., Theilla M., Anbar R., Singer J., Cohen J. Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med 2008, 34:1580-1592.
63. Lee S., Gura K.M., Puder M. Omega-3 fatty acids and liver disease. Hepatology 2007, 45:841-845.
64. Brooks J.D., Milne G.L., Yin H., Sanchez S.C., Porter N.A., Morrow J.D. Formation of highly reactive cyclopentenone isoprostane compounds (A3/J3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem 2008, 283:12043-12055.
65. Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F.S., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem 2007, 282:2529-2537.
66. Tanaka Y., Aleksunes L.M., Yeager R., Gyamfi M.A., Esterly N., Guo G.L., et al. NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 2008, 325:655-664.
67. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana M., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106:635-643.
68. Elizondo A., Araya J., Rodrigo R., Signorini C., Sgherri C., Comporti M., et al. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol Res 2008, 41:59-68.
69. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Blendis L., Halpern Z., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007, 47:711-717.
70. Cortez-Pinto H., Jesus L., Barros H., Lopes C., Moura M.C., Camilo M.E. How different is the dietary pattern in non-alcoholic steatohepatitis patients?. Clin Nutr 2006, 25:816-823.
71. Allard J.P., Aghdassi E., Mohammed S., Raman M., Avand G., Arendt B.M., et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol 2008, 48:300-307.
72. Puri P., Baillie R.A., Wiest M.M., Mirshahi F., Choudhury J., Cheung O., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
73. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37:909-916.
74. Capanni M., Calella F., Biagini M.R., Genise S., Raimondi L., Bedogni G., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006, 23:1143-1151.
75. Spadaro L., Magliocco O., Spampinato D., Piro S., Oliveri C., Alagona C., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40:194-199.
76. Zhu F.S., Liu S., Chen X.M., Huang Z.G., Zhang D.W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008, 14:6395-63400.
77. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008, 42:413-418.
78. Hatzitolios A., Savopoulos C., Lazaraki G., Sidiropoulos I., Haritanti P., Lefkopoulos A., et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004, 23(4):131-134.
79. Vega G.L., Chandalia M., Szczepaniak L.S., Grundy S.M. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med 2008, 56(5):780-785.
80. Cussons A.J., Watts G.F., Mori T.A., Stuckey B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009, 94(10):3842-3848.
81. O'keefe J.H., Gheewala N.M., O'keefe J.O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008, 51(3):249-255.
82. Fraser A., Abel R., Lawlor D.A., Elhayany A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia 2008, 51:1616-1622.